Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia (Q35106637)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia (English)

1 reference

Europe PubMed Central

6 August 2017

1 reference

ChEBI release 2020-05-28

Kazuma Ohyashiki

7

object named as

Kazuma Ohyashiki

1 reference

Europe PubMed Central

6 August 2017

author name string

Seiichi Okabe

1

1 reference

Europe PubMed Central

6 August 2017

Tetsuzo Tauchi

2

1 reference

Europe PubMed Central

6 August 2017

Shinya Kimura

3

1 reference

Europe PubMed Central

6 August 2017

Taira Maekawa

4

1 reference

Europe PubMed Central

6 August 2017

Toshihiko Kitahara

5

1 reference

Europe PubMed Central

6 August 2017

Yoko Tanaka

6

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

28 February 2014

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

9

1 reference

Europe PubMed Central

6 August 2017

e89080

1 reference

Europe PubMed Central

6 August 2017

2

1 reference

Europe PubMed Central

6 August 2017

copyright license

Creative Commons Attribution 4.0 International

28 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Ponatinib in refractory Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Evolution of therapies for chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Clinical studies of histone deacetylase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Histone deacetylases and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Bcr/Abl activates transcription of the Bcl-X gene through STAT5.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Dominant negative MYC blocks transformation by ABL oncogenes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938434

9 July 2018

Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089080

21 January 2018

Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24586514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0089080

1 reference

Europe PubMed Central

6 August 2017

2014PLoSO...989080O

0 references

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35106637&oldid=1862444968"